Poolbeg Pharma (AIM: POLB) has received a Notice of Allowance from the Israeli Patent Office for its POLB 001 patent application covering cancer immunotherapy-induced Cytokine Release Syndrome.

Poolbeg Pharma Plc (AIM: POLB) has raised £3.5 million before expenses through the placing of 58,333,328 new shares at 6p each.

First Patient Dosed in the POLB 001 TOPICAL Clinical Trial Interim data remains on track for summer 2026 and partnering discussions continue to advance with multiple companies

POLB 001 patent granted in South Africa for the treatment or prevention of hypercytokinemia and severe influenza Patent decision strengthens Poolbeg’s intellectual property portfolio

Decision to grant European Patent received for POLB 001 in cancer immunotherapy-induced CRS  Major milestone will provide IP protection in key European markets, strengthening global patent portfolio

Two posters with POLB 001 preclinical data presented at the European Hematology Association Congress

FDA feedback supports Poolbeg’s proposed development pathway for POLB 001, providing further clarity for ongoing partnering discussions

Poolbeg Pharma plc is set to present new data on its drug candidate POLB 001 at the upcoming European Hematology Association Congress 2026, highlighting the treatment’s potential to prevent cancer

Further strengthening of Poolbeg’s global intellectual property portfolio

Poolbeg Pharma PLC (AIM: POLB) is stepping up partnering discussions with multiple pharma groups as it approaches a series of near-term clinical catalysts that could unlock a deal.